Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Weekly semaglutide beats daily liraglutide for weight loss, and the margin is not small. That is the short answer, and it comes from a trial that compared the two drugs directly rather than from indirect guesswork.
But weight loss numbers are only one part of a decision. Dosing burden, side effects, approved use and whether you can actually obtain the drug all matter. This comparison covers each in turn.
What each drug is
Saxenda is liraglutide at 3.0 mg, injected once daily. It is approved specifically for weight management in adults.
Ozempic is semaglutide at 0.5 mg, 1.0 mg or 2.0 mg, injected once weekly. It is approved for type 2 diabetes, not for weight loss.
That last point causes constant confusion. Ozempic is widely used for weight loss, but that use is off-label. The weight-loss-approved version of semaglutide is Wegovy, dosed higher at 2.4 mg weekly.
Both drugs belong to the same class. Both are GLP-1 receptor agonists, meaning they mimic GLP-1 (glucagon-like peptide-1, a hormone your gut releases after eating that tells your brain you have had enough).
The head-to-head evidence
Most drug comparisons rely on comparing separate trials, which is unreliable because the populations differ. Saxenda and semaglutide have something better: a direct comparison.
The STEP 8 trial, published in JAMA in 2022, randomly assigned adults with overweight or obesity but without diabetes to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg over 68 weeks.
Semaglutide produced significantly greater weight loss than liraglutide. The gap was large enough to be clinically meaningful, not just statistically detectable.
The individual trial data lines up with this. In the SCALE trial published in the New England Journal of Medicine, liraglutide 3.0 mg produced an average 8.4 kg loss over 56 weeks. In the STEP 1 trial, semaglutide 2.4 mg produced an average 14.9 percent body weight reduction over 68 weeks.
Different trials, different durations, so the comparison is imperfect. STEP 8 is the one that matters because it removed those variables.
Dosing: the difference people underestimate
| Saxenda | Ozempic | |
|---|---|---|
| Frequency | Daily | Weekly |
| Injections per year | 365 | 52 |
| Titration period | 5 weeks | 8 to 16 weeks |
| Starting dose | 0.6 mg | 0.25 mg |
| Target dose | 3.0 mg | 1.0 to 2.0 mg |
Seven times fewer injections is not a minor convenience difference. It is the main reason semaglutide overtook liraglutide commercially.
Real-world adherence to daily injectables drops off sharply after the first few months. Missed doses matter because GLP-1 appetite suppression depends on steady drug levels. A dose missed on Saxenda means a noticeable gap. On Ozempic, the long half-life smooths that out.
Ozempic escalates more slowly, which usually means gentler side effects during the build-up. Saxenda reaches full dose in five weeks, which some people find abrupt.
Side effects compared
Both drugs cause the same category of side effects, because both work through the same mechanism of slowing stomach emptying.
Nausea, vomiting, diarrhoea and constipation dominate for both. Roughly four in ten users experience nausea on either drug.
The differences are in pattern rather than type. Saxenda's daily dosing means side effects tend to be lower-grade but more constant. Ozempic's weekly dosing concentrates them into the days after each injection for some people, then eases.
Serious risks are shared across the class. Pancreatitis, gallbladder disease and, in people with the relevant family history, medullary thyroid carcinoma concerns apply to both. Neither is used in pregnancy.
Head-to-head, STEP 8 found gastrointestinal side effects were common on both drugs. Neither has a clean tolerability advantage.
Cost
Both are expensive, and neither has an official registered price in Pakistan.
Saxenda costs more per month than it looks, because you use a full pen faster at daily dosing. Ozempic pens last longer per unit.
In Pakistan, both arrive through import channels. Both need refrigeration. Both are subject to the same supply interruptions and exchange rate swings. Semaglutide has faced repeated global shortages driven by weight loss demand, which has made it the less reliably obtainable of the two at various points.
Which is better for what
Choose semaglutide if weight loss is the main goal, you want fewer injections, and you can obtain it consistently. The evidence is clearly stronger.
Consider liraglutide if semaglutide is unavailable, you have tolerated liraglutide before, or your prescriber has a specific reason to prefer daily dosing. Daily dosing can be an advantage if side effects need fine adjustment, because you can stop and restart faster.
Neither is suitable if you have a personal or family history of medullary thyroid carcinoma or MEN2, you are pregnant or breastfeeding, or you have had pancreatitis.
The Pakistan reality
Neither drug is registered for sale in Pakistan. Everything available here comes through import channels, with the pricing, verification and supply continuity problems that follow.
For a comparison to be useful, it has to include the option of actually completing a course. A drug with better trial results that you cannot obtain for six consecutive months will underperform a lesser option you can finish.
This is where locally registered alternatives enter the picture. METASLIM™ sublingual drops work on the same GLP-1 appetite pathway, delivered under the tongue instead of by injection. It is not pharmaceutical semaglutide or liraglutide, and it should not be described as equivalent to either. What it offers is registration, a physician reviewing every order, no cold chain to break, and a supply that does not depend on import channels.
If you want to understand the underlying biology before choosing, our page on how GLP-1 support works explains the pathway both drugs act on. Our full guide to Saxenda covers liraglutide in detail, and Ozempic alternatives compares the wider field.
The verdict
On weight loss, semaglutide wins. STEP 8 settled that directly, and the margin was substantial.
On convenience, semaglutide wins again. Fifty-two injections against three hundred and sixty-five is not a close contest.
On tolerability, they are broadly comparable, with different patterns rather than a clear winner.
On availability in Pakistan, neither is a reliable option, which is the factor that decides it for most people reading this.
To compare complete programs rather than headline efficacy numbers, view the program and current pricing alongside whatever imported option you are considering.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.